Dr. Scott Laurie recently presented longer-term data from the IND227 trial showing that adding pembrolizumab to standard platinum-pemetrexed chemotherapy improved overall survival by 24% compared with chemotherapy alone in advanced pleural mesothelioma.
The expanded analysis also suggested survival benefits with pembrolizumab alone, and the benefit of the combination persists with longer follow-up.
Read the full article:
Dr. Scott Laurie recently presented data from IND227 that showed the combination improved overall survival by 24% compared with chemotherapy alone.
12/24/2025
In this episode, we break down the FDA approval of subcutaneous amivantamab and what it means for lung cancer care.
Host Dr. Narjust Florez is joined by Dr. Natasha Leighl and Dr. Federico Cappuzzo Oncologo to discuss the science behind this approval, the convenience factor of subcutaneous delivery, and the real-world impact for patients, clinicians, and oncology practices.
Whether you’re a clinician, researcher, or patient advocate, this conversation offers key insights into an important shift in treatment delivery. Listen now: https://bit.ly/4qnnoqY
12/22/2025
Connect with the international lung cancer community at the European Lung Cancer Congress 2026.
From cutting-edge science to multidisciplinary care, ELCC 2026 is where progress meets practice.
📝 Secure your place today: https://bit.ly/3KG0yf1
ESMO - European Society for Medical Oncology
12/21/2025
Have you registered for TTLC yet?
The 2026 IASLC Targeted Therapies of Lung Cancer (TTLC) Meeting is approaching, and this is your reminder not to miss one of the most focused, high-impact conferences in thoracic oncology.
From emerging targets to resistance mechanisms and novel trial data, TTLC brings together experts shaping the future of lung cancer care.
What an incredible few days at NACLC! We’re grateful to the speakers, attendees, and partners who made the IASLC ASCO North America Conference on Lung Cancer such a memorable success.
📸 Photos from the event are now available, take a look and relive the highlights: https://bit.ly/4pLuo0V
American Society of Clinical Oncology
12/18/2025
🎉 Welcome VIKTOR!
We’re excited to announce the launch of the Virtual International Knowledgebase for Thoracic Oncology Research (VIKTOR)—a groundbreaking new initiative from the IASLC Basic and Translational Science Committee.
VIKTOR brings together global data on preclinical models, starting with cell lines, into a single, collaborative, and searchable platform. Researchers can easily identify and compare model systems, link them with molecular data, and accelerate discovery in thoracic oncology.
✅ IASLC members now have full access.
Get started today:
1️⃣ Visit the VIKTOR page
2️⃣ Click Access Now
3️⃣ Log in with your IASLC account and start searching
Exciting news!
IASLC has selected the four Co-Chairs of the 2027 World Conference on Lung Cancer (WCLC), happening September 11–14, 2027, in Denver, Colorado.
Meet the 2027 WCLC Co-Chairs:
✨ Sanja Dacic, MD, PhD – Yale School of Medicine
✨ Daniel R. Gomez, MD, MBA – Memorial Sloan Kettering Cancer Center
✨ John V. Heymach, MD, PhD – UT MD Anderson Cancer Center
✨ Sara Najmeh, MD – McGill University
Their combined leadership spans pathology, radiation oncology, targeted therapies, and surgery, helping shape a dynamic, multidisciplinary program focused on improving outcomes for people affected by lung cancer worldwide.
In this special episode, Dr. Narjust Florez and Dr. Stephen Liu break down key highlights from the IASLC | ASCO 2025 North America Conference on Lung Cancer.
- Dr. Igor Odintsov explores updates in diagnostic pathology and how next-generation sequencing is shaping the patient journey.
- Dr. Byoung Chul Cho reviews phase 3 data comparing gotistobart vs. docetaxel in metastatic squamous cell lung cancer.
- Dr. Sulin Wu discusses the impact of family history in lung cancer among women and low-exposure smokers.
⏰ Take advantage of early registration rates until 21 January 2026 and secure your place at this premier meeting.
Don’t miss the opportunity to:
✅ Engage with leading experts across , , , imaging, and
✅ Access cutting-edge science and practical insights shaping care
✅ Network and collaborate with peers from around the world
✅ Enhance your knowledge through multidisciplinary sessions and interactive discussions
12/12/2025
Across the globe, members of the thoracic oncology community are leading research, mentoring colleagues, and improving patient care. 🌍
The IASLC Distinguished Service and Lectureship Awards are your opportunity to recognize leaders and rising stars whose work has made a lasting impact worldwide.
🗓️ Nomination window: Open now through December 24, 2025, 12 PM MST
🗓️ Self-nomination/acceptance: Through January 14, 2026, 12 PM MST
Think of the colleagues who inspire collaboration, advance science, and improve care. Learn more and nominate now: https://bit.ly/4pwDBK9
12/12/2025
Join us at TTLC 2026!
Don’t miss the IASLC Targeted Therapies of Lung Cancer Meeting in Huntington Beach, CA! Connect with global experts, engage with cutting-edge science, and help shape the future of targeted therapies.
- Learn from world-renowned clinicians & researchers
- Expand your professional network
- Discover the latest clinical trial insights
His presence was felt when he walked into any room, whether it was because of his engaging smile, his full beard, the warmth of his voice, the strength of his handshake, the joy of his laugh, or his signature red toque. Angus Pratt was a giant in the lung cancer community, becoming a fierce advocate and friend. He exemplified what it means to move with grace and determination toward an uncertain outcome and used his voice to advocate for research that could transform patient outcomes. So much has been written since his passing earlier this week, and it is a testament to his legacy that we as a community are feeling the weight of his loss. The lung cancer community and the IASLC are better for having known him and worked with him, if only under different circumstances. Angus, you will be remembered; your legacy will be secured. We will continue to do the work, research, and advocacy that meant so much to you. 🕯️🫁
Address
1775 N. Sherman Street, Suite 1600 Denver, CO 80203
Be the first to know and let us send you an email when International Association for the Study of Lung Cancer posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Contact The Practice
Send a message to International Association for the Study of Lung Cancer:
The International Association for the Study of Lung Cancer (IASLC) is on a mission to conquer thoracic cancers worldwide. Through hosting global conferences, funding cutting-edge research and educating the health care community and the general public on all aspects of thoracic cancers, the IASLC strives to alleviate the burden lung cancer places on patients, families and communities.
Each year, the IASLC hosts the World Conference on Lung Cancer (WCLC), the world’s largest meeting dedicated solely to thoracic cancers. The WCLC regularly attracts over 7,000 thoracic cancer specialists from over 100 countries and offers attendees the chance to collaborate and network while learning about the latest updates in the field.
The IASLC Foundation supports the education of research fellows - who are the next generation of lung cancer physicians and scientists - by funding research fellowships. Since its inception, the foundation has given nearly $3.5 million to lung cancer research, and that number is on the rise.
Additionally, the IASLC publishes the Journal of Thoracic Oncology (JTO), a primary source for educational information related to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Over its publication history, the JTO has established itself as an authoritative resource in the field, and the journal recently saw its impact factor increase from 6.595 in 2016 to 10.336 in 2017.
The IASLC is a global and multidisciplinary organization that desires to build a international and inclusive lung cancer community. Whether you are an oncologist or surgeon, advocate or patient, we welcome your expertise, experience and voice in the ongoing fight against lung cancer. Join us!
